A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®

NCT02028312 · clinicaltrials.gov ↗

PHASE4

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Per Sponsor

Conditions

Dry Eye Disease

Interventions

DRUG: Loteprednol etabonate
DRUG: Artificial Tears
DRUG: Restasis

Sponsor

Edward Holland, MD